Novavax Inc stated on Thursday its two-dose vaccine was 80% efficient towards Covid-19 in a late-stage trial testing the shot in teenagers aged 12 to 17 years.
The trial concerned 2,247 adolescents and passed off between May and September final 12 months when the Delta variant was the dominant pressure within the United States. The vaccine was 82% efficient towards the variant.
The US biotech stated it expects to submit functions to international regulators for the shot’s use in adolescents in the course of the first quarter.
Novavax late final month filed for authorization of the shot in US adults, a much-awaited step following months of struggles with improvement and manufacturing issues.The vaccine has acquired authorizations from the European Union and the World Health Organization and has been cleared to be used in adults in international locations together with the United Kingdom and New Zealand.
In the corporate’s trial in adults, which enrolled about 30,000 members within the United States and Mexico, the vaccine had an efficacy of 90.4%.
Novavax stated it didn’t see any incidents of myocarditis within the adolescent knowledge however stated it was retaining a detailed eye on the inflammatory coronary heart situation and every other antagonistic occasions because it deploys its vaccine within the broader inhabitants.
“So as we deploy the vaccine within the broader inhabitants, we’re retaining a really shut eye on this and the opposite antagonistic occasions related to vaccination. We can be sure we inform the general public and regulators about how our most efficiency from security perspective,” stated Filip Dubovsky, chief medical officer.
,
With inputs from TheIndianEXPRESS
